Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046040/SEA-CD70 safety study in myeloid malignancies
NL-OMON60632Phase 1Active, not recruiting
- Sponsor
- Seagen Inc.
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SEA-CD70 in myeloid diseases and acute myeloid leukemia (AML), sponsored by Seagen Inc. Primary endpoint: Primary endpoint(s). Started Jan 2022; status: active, not recruiting.
02
Drugs
SEA-CD70
03
Conditions
myeloid diseasesacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60632.